Defence Therapeutics Inc. DTC
CNSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -59.53% | 121.41% | |||
| Depreciation & Amortization | 2.99% | -43.22% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.49% | 126.42% | |||
| Operating Income | 14.49% | -126.42% | |||
| Income Before Tax | -97.82% | -113.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -97.82% | -113.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -97.82% | -113.83% | |||
| EBIT | 14.49% | -126.42% | |||
| EBITDA | 14.61% | -128.53% | |||
| EPS Basic | -85.79% | -111.83% | |||
| Normalized Basic EPS | -86.18% | -112.07% | |||
| EPS Diluted | -85.79% | -111.83% | |||
| Normalized Diluted EPS | -86.18% | -112.07% | |||
| Average Basic Shares Outstanding | 6.65% | 1.14% | |||
| Average Diluted Shares Outstanding | 6.65% | 1.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||